

Quality improvement initiative: Early mobilisation post stroke

Lisa Marshall

Specialist physiotherapist in stroke
Colchester Hospital

Outline

- Early mobilisation
- Implementation of Very early mobilisation at Colchester stroke unit
- AVERT phase III trial publication
- Its impact and protocol change
- Results of prespecified dose response analysis
- Participation in AVERT Dose trial - our experience

What is early mobilisation

- Out of bed activity
 - Active Sitting
 - Standing
 - Walking
- Very early mobilisation within 24 hours
- Early mobilisation within first 48 hours
- Mobility Interventions in the first couple of weeks

Early mobilization: Potential benefits

- Potential benefits of early mobilisation:
- Reduce infections such as Aspiration pneumonia, UTI
- Reduce risk of DVT/PE
- Reduce pressure ulcers
- Reduce deconditioning
- Improve recovery and functional outcomes
- Optimise window of opportunity for brain recovery and neuroplasticity

Early mobilization: The potential risks

- Too much too soon could be harmful
 - Reduced cerebral blood flow
 - Negative impacts on neuroplastic changes
- Optimum timing and dosage remains unclear for clinicians

Very early mobilisation project -2012

- Many clinical discussions and disagreements
- AVERT phase II, RCP guidelines, NICE guidelines
- Very Early mobilisation (within first 24 hours stroke onset) project initiated in 2012



The evidence

- **Most guidelines recommended very early mobilisation**
- **RCP consensus**
- **AVERT phase II - VEM safe and feasible**

(Bernhardt et al. A very early rehabilitation trial for stroke (AVERT): phase II safety and feasibility. Stroke. 2008 Feb;39(2):390-6)

- **Earlier and more intensive mobilization after stroke may fast-track return to unassisted walking and improve functional recovery**

(Cumming et al. Very early mobilization after stroke fast-tracks return to walking: further results from the phase II AVERT randomized controlled trial. Stroke. 2011 Jan;42(1):153-8)

Quality improvement project

Application of evidence to practice

Local eligibility criteria created

Education forums & practical teaching sessions for nursing staff

Early mobility champions

Very Early Mobilisation (VEM) Programme	
All criteria below must be met for patient to participate in Very Early Mobilisation	
• 18 years and over	<input type="checkbox"/>
• Medically stable to participate in VEM to be discussed with doctor if any doubt	<input type="checkbox"/>
• <u>Non-Thrombolysed</u> patient If thrombolysed, 24 hour CT scan needs to be completed and patient deemed safe to participate by a doctor	<input type="checkbox"/>
• Not on palliative pathway of care	<input type="checkbox"/>
• GCS \geq 12 /15	<input type="checkbox"/>
• Systolic blood pressure between 110-180 mm Hg	<input type="checkbox"/>
• Oxygen saturation of \geq 92% with or without supplementation	<input type="checkbox"/>
• Heart rate 40 – 100	<input type="checkbox"/>
• Temperature $<$ 38°C	<input type="checkbox"/>
Date of VEM Assessment...../...../..... Suitable Yes <input type="checkbox"/> No <input type="checkbox"/>	
First time out of bed Date...../...../..... Time.....	
Therapeutic handling assessment.....	
Seating.....	
Reason if not mobilised within 24 hours of admission :	
Medically unstable <input type="checkbox"/>	
Staff resources <input type="checkbox"/>	
Seating resources <input type="checkbox"/>	
Palliative care <input type="checkbox"/>	
<u>Thrombolysed</u> <input type="checkbox"/>	
Other.....	
Name of person completing:	
Signature:	
Name and signature of trained nurse	

Very Early Mobilisation (VEM)

Local audit results

- 11 month period in 2013
- 71% met the VEM criteria
- 69% were mobilized within 24 hours
- Protocol facilitated patients admitted outside 8- 4 to be mobilised by the nursing team

AVERT PHASE III Trial, 2015

	Very early mobilisation (n=1054)	Usual care (n=1050)	p value	Median shift (95% CI)
Time to first mobilisation (h)	18.5 (12.8-22.3; n=1042*)	22.4 (16.5-29.3; n=1036*)	<0.0001	4.8 (4.1-5.7)
Frequency per person†	6.5 (4.0-9.5)	3 (2.0-4.5)	<0.0001	3 (3-3.5)
Daily amount per person (min)‡	31 (16.5-50.5)	10 (0-18)	<0.0001	21.0 (20-22.5)
Total amount per person (min)§	201.5 (108-340)	70 (32-130)	<0.0001	117 (107-128)

Fewer patients in the very early mobilisation group had a favourable outcome than those in the usual care group (n=480 [46%] vs n=525 [50%]; adjusted odds ratio [OR] 0.73, 95% CI 0.59-0.90; p=0.004)

88 (8%) patients died in the very early mobilisation group compared with 72 (7%) patients in the usual care group (OR 1.34, 95% CI 0.93-1.93, p=0.113)

- Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial - *Lancet* 2015; 386: 46-55

Early mobilisation criteria updated 2016

Early Mobilisation Programme	
Date of stroke onset...../...../..... Time of stroke onset.....	
<24 hrs post stroke onset	24 - 48 hrs post stroke onset
<ul style="list-style-type: none"> • 18 years and over <input type="checkbox"/> 	<ul style="list-style-type: none"> • 18 years and over <input type="checkbox"/>
<ul style="list-style-type: none"> • Medically stable to participate in Early Mobilisation <input type="checkbox"/> (Not suitable for patients with thrombolysis early neurological deterioration, planned surgery, suspected PE, and unstable coronary conditions - To be discussed with consultant) 	<ul style="list-style-type: none"> • Medically stable to participate in Mobilisation <input type="checkbox"/> (Not suitable for patients with suspected fracture or PE or acute coronary syndrome, to be confirmed with medical team if any concerns)
<ul style="list-style-type: none"> • Not on palliative pathway of care <input type="checkbox"/> 	<ul style="list-style-type: none"> • Not on palliative pathway of care <input type="checkbox"/>
<ul style="list-style-type: none"> • GCS 15 or 14 (losing 1 point by confusion) <input type="checkbox"/> 	<ul style="list-style-type: none"> • GCS >12 in right sided strokes and >10(E3, V1, M6) in left sided strokes <input type="checkbox"/>
<ul style="list-style-type: none"> • Systolic blood pressure between 110-180 mm Hg <input type="checkbox"/> 	<ul style="list-style-type: none"> • Systolic blood pressure between 100-200 mm Hg <input type="checkbox"/>
<ul style="list-style-type: none"> • Oxygen saturation of ≥ 92% with or without supplementation <input type="checkbox"/> 	<ul style="list-style-type: none"> • Oxygen saturation of ≥ 92% with or without supplementation <input type="checkbox"/>
<ul style="list-style-type: none"> • Heart rate 40 – 110 <input type="checkbox"/> 	<ul style="list-style-type: none"> • Heart rate 40 – 110 <input type="checkbox"/>
<ul style="list-style-type: none"> • Temperature <38°C <input type="checkbox"/> 	<ul style="list-style-type: none"> • Temperature <38°C <input type="checkbox"/>
<ul style="list-style-type: none"> • Requires little or no assistance to move <input type="checkbox"/> 	<ul style="list-style-type: none"> • Patients meeting <i>all</i> the above criteria and who have difficulty moving after their stroke should be offered short, frequent mobilisations starting between 24-48 hours post stroke. If > 48 hours post stroke and above criteria is not met please discuss with medical team for suitability to mobilise.
<p>Patients meeting <i>all</i> the above criteria may mobilise within 24 hours post stroke. GTN or infusions are not a contraindication to mobilisation</p>	
Date of Assessment...../...../..... Suitable Yes <input type="checkbox"/> No <input type="checkbox"/>	
First time out of bed Date...../...../..... Time.....	
Reason if first time out of bed delayed :	
Name of person completing:	
Signature: (and counter signature if required)	

Early Mobilisation

Prespecified dose-response analysis for A Very Early Rehabilitation Trial (AVERT)

Neurology® 2016;86:1-8

- Increased daily frequency of out-of-bed sessions (keeping time to first mobilization and mobilization amount constant) improved the odds of favourable outcome in efficacy and safety outcomes

(odds ratio [OR] 1.13, 95% confidence interval [CI] 1.09 to 1.18, p, 0.001)

- Increased amount (minutes per day) of mobilization reduced the odds of a good outcome

(OR 0.94, 95% CI 0.91 to 0.97, p, 0.001)

Rationale for AVERT DOSE Trial

- Dose analyses showed benefit in those less severely affected (mild and moderate strokes) under certain conditions

Clinicians still not clear on what is the optimum dose of mobility therapy

Funding for AVERT DOSE
obtained



Colchester initiated as a recruiting site for AVERT Dose in September 2022


I became Principal investigator and obtained funding through Greenshoots scheme

Multi-arm, Multi-stage, Covariate-adjusted, response- adaptive randomised trial to Determine Optimal early mobility training after Stroke



- Aim: To define the optimal early mobility intervention regimens for people with mild and moderate stroke
- Hypotheses: The optimal dose intervention regimen(s) will result in:
 1. More patients experiencing no or little disability at 3 months post stroke, (primary outcome)
 2. Patients experiencing fewer and less severe complications
 3. Better quality of life at 6 months

Multi-Arm, Multi-Stage, Covariate-Adjusted Response-Adaptive (CARA) Randomisation Design



6 months
End of trial

DOSE
Varying amount
Varying frequency
Tailored to patient

Number of participants:
n > 2,500
approx. 50 hospitals (35)

Mild severity strata (NIHSS = 0-7)

Moderate severity strata (NIHSS = 8-16)

Where are we now?

- Colchester recruitment - 9 participants
- UK recruitment (8 sites) - 44 participants
- International recruitment - nearly 500 in total
- Recruitment end December 2024, published results to follow

Conclusions: Early mobilisation

- VEM (less than 24 hours) may be associated with clinical harm
- VEM may be appropriate in some cases - patients requiring little or no assistance to mobilise
- Low-quality evidence from an exploratory network meta-analysis indicated that mobilisation at around 24 hours may be associated with the best outcome (Langhorne et al. Cochrane Database Syst Rev. 2018)
- Increased daily frequency of out-of-bed sessions may be beneficial - further evidence is awaited - AVERT Dose

Summary: quality improvement project

- Our experience in implementation of very early mobilisation, subsequent changes to the pathway, therapy-led participation in AVERT Dose trial has galvanised the multidisciplinary team and enabled our MDT to focus on this important area
- It has contributed to improved outcomes as evident in our below national stroke specific mortality
- It has raised the profile of AHPs and improved confidence amongst therapy teams in delivering QI projects and research activities

Thank you for listening



Questions?